Pharmacological management of seizures and status epilepticus in critically ill patients

Journal of Pharmacy Practice

Volumn 23, Issue 5, 2010, Pages 441-454

  Tesoro, Eljim P ^a   Brophy, Gretchen M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

critically ill; intensive care unit; prophylaxis; seizures; status epilepticus

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; HARKOSERIDE; KETAMINE; LORAZEPAM; MIDAZOLAM; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; THIOPENTAL; TOPIRAMATE; VALPROIC ACID;

ACUTE DISEASE; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CRITICALLY ILL PATIENT; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; EMERGENCY CARE; EPILEPTIC STATE; FLUID THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART OUTPUT; HEART RATE; HUMAN; HYPERAMMONEMIA; HYPERTENSION; HYPOTENSION; INTRACRANIAL PRESSURE; LIVER TOXICITY; METABOLIC ACIDOSIS; MORBIDITY; MORTALITY; NEUROLOGIC EXAMINATION; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHLEBITIS; PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TRAUMATIC BRAIN INJURY;

EID: 78649944132     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010372321     Document Type: Review

References (103)

1. Commission on Classification of Terminology, International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981 ; 22 (4). 489-501.
2. Lowenstein D., Bleck T., Macdonald RL It's time to revise the definition of status epilepticus. Epilepsia. 1999 ; 40 (1). 120-122.
3. DeLorenzo RJ, Pellock JM, Towne AR, et al. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995 ; 12 (4). 316-328.
4. Penberthy LT, Towne A., Garnett LK, et al. Estimating the economic burden of status epilepticus to the health care system. Seizure. 2005 ; 14 (1). 46-51.
5. DeLorenzo RJ Epidemiology and clinical presentation of status epilepticus. Adv Neurol. 2006 ; 97: 199-215.
6. Chin RF, Neville BG, Peckham C., et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective, population-based study. Lancet. 2006 ; 368 (9531). 222-229.
7. Hauser WA Status epilepticus: epidemiologic considerations. Neurology. 1990 ; 40 (5 suppl 2). 9-13.
8. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996 ; 46 (4). 1029-1035.
9. Lowenstein DH, Alldredge BK Status epilepticus. N Engl J Med. 1998 ; 338 (14). 970-976.
10. Pitkanen A. Efficacy of current antiepileptics to prevent neurodegredation in epilepsy models. Epilepsy Res. 2002 ; 50 (1-2). 141-160.
11. Jones DM, Esmaeil N., Maren S., et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res. 2002 ; 50 (3). 301-312.
12. Brooks-Kayal A., Shumate M., Rikhter T., et al. Selective changes in single cell GABA A receptor subunit expression and function in temporal lobe epilepsy. Nat Med. 1998 ; 4 (10). 1166-1172.
13. Wasterlain CG, Fujikawa DG, Penix L., et al. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia. 1993 ; 34 (suppl 1). S37 - S53.
14. Lothman E. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990 ; 40 (5 suppl 2). 13-23.
15. Alldredge BK, Lowenstein DH, Simon RP Seizures associated with recreational drug abuse. Neurology. 1989 ; 39 (8). 1037-1039.
16. Thabet F., Al Maghrabi M., Al Barraq A., et al. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care. 2009 ; 10 (3). 347-351.
17. Spriet I., Govens J., Meersseman W., et al. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007 ; 41 (7). 1130-1136.
18. Legriel S., Mourvillier B., Bele N., et al. Outcomes in 140 critically ill patients with status epilepticus. Intensive Care Med. 2008 ; 34 (3). 476-480.
19. Rossetti AO, Bromfield EB Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol. 2005 ; 54 (1). 34-38.
20. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med. 1998 ; 339 (12). 792-798.
21. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983 ; 249 (11). 1452-1454.
22. Fountain NB, Adams RE Midazolam treatment of acute and refractory status epilepticus. Clin Neuropharmacol. 1999 ; 22 (5). 261-267.
23. Towne AR, DeLorenzo RJ Use of intramuscular midazolam for status epilepticus. J Emerg Med. 1999 ; 17 (2). 323-328.
24. Scott RC, Besag FM, Boyd SG, et al. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia. 1998 ; 39 (3). 290-294.
25. Kendall JL, Reynolds M., Goldberg R. Intranasal midazolam in patients with status epilepticus. Ann Emerg Med. 1997 ; 29 (3). 415-417.
26. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990 ; 323 (8). 497-502.
27. Berning S., Boesebeck F., van Baalen A., et al. Intravenous levetiracetam as treatment for status epilepticus. J Neurol. 2009 ; 256 (10). 1634-1642.
28. Bratton SL, Chestnut RM, Ghajar J., et al. Antiseizure prophylaxis. J Neurotrauma. 2007 ; 24 (suppl 1). S83 - S86.
29. Evans WE, Schentag JJ, Jusko WJ, et al. Applied Pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics ; 1992.
30. Anderson GS, Pak C., Doane KW, et al. Revised winter-tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother. 1997 ; 31 (3). 279-284.
31. Chokshi R., Openshaw J., Mehta NN, et al. Purple glove syndrome following intravenous phenytoin administration. Vasc Med. 2007 ; 12 (1). 29-31.
32. Pryor FM, Gidal B., Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia. 2001 ; 42 (2). 245-250.
33. Mazarati AM, Baldwin RA, Sankar R., et al. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998 ; 814 (1-2). 179-185.
34. Limdi NA, Shimpi AV, Faught E., et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005 ; 64 (2). 353-355.
35. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus-experience in 102 adult patients. Seizure. 2005 ; 14 (3). 164-169.
36. Hodges BM, Mazur JE Intravenous valproate in status epilepticus. Ann Pharmacother. 2001 ; 35 (11). 1465-1470.
37. Uberall MA, Trollman R., Wundsiedler U., et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000 ; 54 (11). 2188-2180.
38. Agarwal P., Kumar N., Chandra R., et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007 ; 16 (6). 527-532.
39. Gilad R., Izkovitz N., Dabby R., et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008 ; 118 (5). 296-300.
40. Lheureux PE, Penaloza A., Zahir S., et al. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence ? Crit Care. 2005 ; 9 (5). 431-440.
41. Lynch BA, Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 ; 101 (26). 9861-9866.
42. Ruegg S., Naegelin Y., Hardmeier M., et al. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav. 2008 ; 12 (3). 477-480.
43. Nau KM, Divertie GD, Valentino AK, et al. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care. 200 9; 11 (1). 34-37.
44. Rossetti AO, Bromfield EB Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006 ; 8 (3). 651-654.
45. Au Yeung SC, Ensom MH Phenytoin and enteral feedings: does evidence support an interaction ? Ann Pharmacother. 2000 ; 34 (7-8). 896-905.
46. Clark-Schmidt AL, Garnett WR, Lowe DR, et al. Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm. 1990 ; 47 (9). 2034-2037.
47. Ferrell PB, McLeod HL Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 ; 9 (10). 1543-1546.
48. Kuehn BM FDA: epilepsy drugs may carry skin risks for Asians. JAMA. 2008 ; 300 (24). 2845.
49. Hung CC, Lin CJ, Chen CC, et al. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/ CYP2C19 polymorphisms. Ther Drug Monit. 2004 ; 26 (5). 534-540.
50. Mayer SA, Claassen J., Lokin J., et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002 ; 59 (2). 205-210.
51. Drislane FW, Lopez MR, Blum AS, et al. Detection and treatment of refractory status epilepticus in the intensive care unit. J Clin Neurophysiol. 2008 ; 25 (4). 181-186.
52. Claassen J., Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia. 2002 ; 43 (2). 146-153.
53. Bleck TP Refractory status epilepticus. Curr Opin Crit Care. 2005 ; 11 (2). 117-120.
54. Marik PE, Varon J. The management of status epilepticus. Chest. 2004 ; 126 (2). 582-591.
55. Kalviainen R., Eriksson K., Parviainen I. Refractory generalized convulsive status epilepticus-a guide to treatment. CNS Drugs. 2005 ; 19: 759-768.
56. Parent JM, Lowenstein DH Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology. 1994 ; 44 (10). 1837-1840.
57. Claassen J., Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 2001 ; 57 (6). 1036-1042.
58. Ulvi H., Yoldas T., Mungen B., et al. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci. 2002 ; 23 (4). 177-182.
59. Nantoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology. 2000 ; 54 (6). 1366-1368.
60. Jones PJ, Wang Y., Smith MD, et al. Hydroxyamide analogs of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity. J Pharmacol Exp Ther. 2007 ; 320 (2). 828-836.
61. Kang TM Propofol infusion syndrome in critically ill patients. Ann Pharmacother. 2002 ; 36 (9). 1453-1456.
62. Iyer VN, Hoel R., Rabinstein AA Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009 ; 37 (12). 3024-3030.
63. Fong JJ, Sylvia L., Ruthazer R., et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med. 2008 ; 36 (8). 2281-2287.
64. Sneyd JR Propofol and epilepsy. Br J Anaesthesia. 1999 ; 82 (6). 168-169.
65. Van Ness PC Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia. 1990 ; 31 (1). 611-617.
66. Krishnamurthy KB, Drislane FW Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999 ; 40 (6). 759-762.
67. Parviainen I., Uusaro A., Kalviainen R., et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002 ; 59 (8). 1249-1251.
68. Abend NS, Florance N., Finkel RS, et al. Intravenous levetiracetam terminates refractory focal status epilepticus. Neurocrit Care. 2009 ; 10 (1). 83-86.
69. Patel NC, Landan IR, Levin J., et al. The use of levetiracetam in refractory status epilepticus. Seizure. 2006 ; 15 (3). 137-141.
70. Uges JWF, van Huizen MD, Engelsman J., et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia. 2009 ; 50 (3). 415-421.
71. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000 ; 42 (2-3). 117-122.
72. Pruss H., Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008 ; 82 (2-3). 219-222.
73. Sheth RD, Gidal BE Refractory status epilepticus: response to ketamine. Neurology. 1998 ; 51 (6). 1765-1766.
74. Ubogu EE, Sagar SM, Lerner AJ, et al. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003 ; 4 (1). 70-75.
75. Bleck TP, Quigg MS, Nathan BR, et al. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia. 2002 ; 43 (suppl 1): 282.
76. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology. 2003 ; 60 (2). 332-334.
77. Doty P., Rudd GD, Stoehr T., et al. Lacosamide. Neurotherapeutics. 2007 ; 4 (1). 145-148.
78. Tilz C., Resch R., Hofer T., et al. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia. 2010 ; 51 (2). 316-317.
79. Kellinghaus C., Berning S., Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009 ; 14 (2). 429-431.
80. Chumnanvej S., Dunn IF, Kim DH, et al. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007 ; 60 (1). 99-102.
81. Rosengart AJ, Huo D., Tolentino J., et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg. 2007 ; 107 (2). 253-260.
82. Naidech AM, Kreiter KT, Janjua N., et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005 ; 36 (3). 583-587.
83. Bederson JB, Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009 ; 40 (3). 994-1025.
84. Molyneux AJ, Kerr RS, Yu LM, et al. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005 ; 366 (9488). 809-817.
85. Vespa PM, O'Phelan K., Shah M., et al. Acute seizures after intracerebral hemorrhage. Neurology. 2003 ; 60 (9). 1441-1446.
86. Passero S., Rocchi R., Rossi S., et al. Seizures after spontaneous supratentorial intracerebral hemorrhage. Epilepsia. 2003 ; 43 (10). 1175-1180.
87. Messe SR, Sansing LH, Cuccchiara BL, et al. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care. 2009 ; 11 (1). 38-44.
88. Naidech AM, Garg RK, Liebling S., et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009 ; 40 (12). 3810-3815.
89. Tremont-Lukats IW, Ratilal BO, Armstrong T., et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008 ;(2). CD004424.
90. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004 ; 79 (12). 1489-1494.
91. Ahmed I., Reichenberg J., Lucas A., et al. Erythema multiforme associated with phenytoin and cranial radiation therapy: A report of three patients and review of the literature. Int J Dermatol. 2004 ; 43 (1). 67-73.
92. Grossman SA, Hochberg F., Fisher J., et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol. 1998 ; 42 (2). 118-126.
93. Milligan TA, Hurwitz S., Bromfield EB Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008 ; 71 (9). 665-669.
94. Lin CL, Dumont AS, Lieu AS, et al. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003 ; 99 (6). 978-985.
95. Berger AR, Lipton RB, Lesser ML, et al. Early seizures following intracerebral hemorrhage: implications for therapy. Neurology. 1988 ; 38 (9). 1363-1365.
96. Broderick JP, Adams HP Jr, Barsan W., et al. Guidelines for the management of spontaneous intracerebral hemorrhage. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 1999 ; 30 (4). 905-915.
97. Glantz M., Cole B., Forsyth P., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors- report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000 ; 54 (10). 1886-1893.
98. Vecht C., van Breemen M. Optimizing therapy of seizures in specific clinical situations. Neurology. 2006 ; 67 (12 suppl 4). S10 - S13.
99. Liu KC, Bhardwaj A. Use of prophylactic anticonvulsants in neurologic critical care: a critical appraisal. Neurocrit Care. 2007 ; 7 (2). 175-184.
100. Ratilal B., Costa J., Sampaio C. Anticonvulsants for preventing seizures in patients with chronic subdural haematoma. Cochrane Database Syst Rev. 2005 ;(3). CD004893.
101. Swan J., Wood E. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev. 2010 ;(1). CD005398.
102. Shah D., Husain AM Utility of levetiracetam in patients with subarachnoid hemorrhage. S\eizure. 2009 ; 18 (10). 676-679.
103. Brophy GM, Tesoro EP Status epilepticus. In: Chisolm-Burns MA, Wells B, Schwinghammer T, et al, eds. Pharmacotherapy Principles & Practice. 1st ed. New York: McGraw-Hill ; 2008: 467.